Related references
Note: Only part of the references are listed.Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.
J. M. Besterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
M. M. Eatock et al.
ANNALS OF ONCOLOGY (2013)
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
M. Peeters et al.
BRITISH JOURNAL OF CANCER (2013)
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
Toshihiko Doi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
Christopher Daly et al.
CANCER RESEARCH (2013)
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis
Tokuhiro Matsubara et al.
HEPATOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma
Archana Bhaskar et al.
LEUKEMIA RESEARCH (2013)
A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors
Markus Thomas et al.
PLOS ONE (2013)
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Moritz Felcht et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Testing for Discordance at Metastatic Relapse of Breast Cancer Matters Reply
Naoki Niikura et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Synthesis and Biological Profile of the pan-Vascular Endothelial Growth Factor Receptor/Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor-Like Homology Domains 2 (VEGF-R/TIE-2) Inhibitor 11-(2-Methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): A Novel Oncology Therapeutic Agent
Robert L. Hudkins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell-Cell Junctions and Lung Metastasis
Tanja Holopainen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617
Nikolett Molnar et al.
MICROVASCULAR RESEARCH (2012)
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen et al.
LANCET ONCOLOGY (2012)
Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
Michele De Palma et al.
CLINICAL CANCER RESEARCH (2011)
Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
Hanhua Huang et al.
CLINICAL CANCER RESEARCH (2011)
Angiopoietin-1/Tie2 Signal Augments Basal Notch Signal Controlling Vascular Quiescence by Inducing Delta-Like 4 Expression through AKT-mediated Activation of β-Catenin
Jianghui Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Angiopoietin-2, an Angiogenic Regulator, Promotes Initial Growth and Survival of Breast Cancer Metastases to the Lung through the Integrin-linked Kinase (ILK)-AKT-B Cell Lymphoma 2 (Bcl-2) Pathway
Yorihisa Imanishi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Update on Therapy of Chronic Lymphocytic Leukemia
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor.
D. S. Mendelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience.
P. J. O'Dwyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
Rossana Maffei et al.
BLOOD (2010)
Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
Young Jun Koh et al.
CANCER CELL (2010)
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hiroya Hashizume et al.
CANCER RESEARCH (2010)
Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
Sung-Suk Chae et al.
CLINICAL CANCER RESEARCH (2010)
Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2010)
Optimal Lesion Number for Evaluation of Tumor Response in Response Evaluation Criteria in Solid Tumors
Mark A. Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Jeffrey L. Brown et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
Angela Coxon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
Iris Helfrich et al.
CLINICAL CANCER RESEARCH (2009)
Serum Level of Soluble Vascular Cell Adhesion Molecule 1 Is a Valuable Prognostic Marker in Colorectal Carcinoma
Yoshinaga Okugawa et al.
DISEASES OF THE COLON & RECTUM (2009)
Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis
R. Srirajaskanthan et al.
ENDOCRINE-RELATED CANCER (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme
Mariska Sie et al.
JOURNAL OF NEUROSURGERY (2009)
Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
Hai Tao Yuan et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
Hellmut G. Augustin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Angiogenic Switch of Angiopietins-Tie2 System and Its Prognostic Value in Bladder Cancer
Tibor Szarvas et al.
CLINICAL CANCER RESEARCH (2008)
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
Konstantinos Anargyrou et al.
HAEMATOLOGICA (2008)
Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma
Arne Scholz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia
C. Schliemann et al.
LEUKEMIA (2007)
Angiopoietin: A TIE(d) balance in tumor angiogenesis
Winston S. N. Shim et al.
MOLECULAR CANCER RESEARCH (2007)
Serum angiopoietin-2 as a clinical marker for lung cancer
Joo Hun Park et al.
CHEST (2007)
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer
Mary Anna Venneri et al.
BLOOD (2007)
Expressions and clinical significances of angiopoietin-1,-2 and Tie2 in human gastric cancer
J Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Molecular lymphangiogenesis: new players
T Tammela et al.
TRENDS IN CELL BIOLOGY (2005)
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo
N Jendreyko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Angiopoietins in tumours: the angiogenic switch
CR Tait et al.
JOURNAL OF PATHOLOGY (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model
MR Machein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival
C Sfiligoi et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo
IB Lobov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer
K Hata et al.
ONCOLOGY (2002)
Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma
J Pomyje et al.
MELANOMA RESEARCH (2001)
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
P Carmeliet et al.
NATURE MEDICINE (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas
MP Wong et al.
LUNG CANCER (2000)
Share Paper
